Capstone Investment Advisors LLC Buys Shares of 13,066 Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Capstone Investment Advisors LLC purchased a new position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 13,066 shares of the company’s stock, valued at approximately $48,000.

Other hedge funds have also recently made changes to their positions in the company. Anfield Capital Management LLC bought a new position in Zentalis Pharmaceuticals in the second quarter worth about $40,000. Aigen Investment Management LP purchased a new position in shares of Zentalis Pharmaceuticals in the 3rd quarter worth approximately $41,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Zentalis Pharmaceuticals by 63.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock worth $50,000 after acquiring an additional 5,333 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Zentalis Pharmaceuticals during the second quarter valued at approximately $58,000. Finally, Algert Global LLC acquired a new stake in Zentalis Pharmaceuticals in the second quarter valued at approximately $78,000.

Zentalis Pharmaceuticals Stock Down 0.6 %

Zentalis Pharmaceuticals stock opened at $3.61 on Monday. The stock has a 50-day moving average price of $3.36 and a 200 day moving average price of $4.82. The company has a market capitalization of $257.27 million, a price-to-earnings ratio of -1.45 and a beta of 1.74. Zentalis Pharmaceuticals, Inc. has a 52 week low of $2.66 and a 52 week high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.36. Research analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -2.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ZNTL. Oppenheimer reaffirmed an “outperform” rating and set a $20.00 price target on shares of Zentalis Pharmaceuticals in a research report on Monday, September 16th. Guggenheim reduced their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a report on Friday, November 15th. Finally, Wedbush upgraded Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price target on the stock in a research note on Monday, August 12th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $10.00.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.